Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMR Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
NCT00119730Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2005
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL), sponsored by Dana-Farber Cancer Institute. Started Feb 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00119730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119730.